Adeno-associated virus factor VIII vectors, associated viral particles and therapeutic formulations comprising the same
The invention provides adeno-associated virus (AAV) Factor VIII (FVIII)-encoding/expressing vectors and virus, including AAV FVIII vectors with high expression activity and AAV FVIII vectors that express full-length or truncated functional FVIII protein. The invention also relates to methods of making the herein described AAV FVIII vectors, recombinant AAV FVIII virus particles comprising or expressing such vectors, associated pharmaceutical formulations comprising the same and therapeutic uses thereof.
1. A method of treating a subject suffering from hemophilia A comprising administering a pharmaceutical formulation to said subject by intravenous administration,
wherein the pharmaceutical formulation comprises a recombinant AAV-FVIII virus, sodium phosphate dibasic at a concentration of from about 0.1 mg/ml to about 3 mg/ml, sodium phosphate monobasic monohydrate at a concentration of from about 0.1 mg/ml to about 3 mg/ml, sodium chloride at a concentration of from about 1 mg/ml to about 20 mg/ml, mannitol at a concentration of from about 5 mg/ml to about 40 mg/ml, and poloxamer 188 at a concentration of from about 0.1 mg/ml to about 4 mg/ml,
wherein the recombinant AAV-FVIII virus comprises a vector comprising an AAV2 5′ inverted terminal repeat (ITR), a liver specific transcriptional regulatory region, a FVIII nucleic acid sequence that encodes a functionally active FVIII protein, a polyadenylation sequence, an AAV2 3′ ITR, and optionally one or more introns inserted into the FVIII coding sequence or between the promoter and the FVIII coding sequence, wherein the functionally active FVIII coding region nucleic acid sequence comprises nucleotides 403-4776 of SEQ ID NO: 1 wherein expression of the FVIII from the recombinant AAV-FVIII in the subject treats the hemophilia A.
2. The method of claim 1 , wherein said recombinant AAV FVIII virus comprises an AAV5 capsid protein.
3. The method of claim 1 , wherein the pharmaceutical formulation comprises from about 1E12 vg/kg to about 1E14 vg/kg of the recombinant AAV FVIII virus from about 6E12 vg/kg to about 6E13 vg/kg of the recombinant AAV FVIII virus.
4. The method of claim 1 , wherein the treated subject expresses at least about 5 IU/dl of functional Factor VIII protein after administration of the pharmaceutical formulation.
5. The method of claim 1 , wherein the treated subject expresses at least about 1 IU/dl functional Factor VIII protein after administration of the pharmaceutical formulation.
6. The method of claim 1 , wherein said subject is treated prophylactically with a corticosteroid at a concentration ranging from 5 mg/day to 60 mg/day before or after administration of the pharmaceutical formulation.
7. The method of claim 1 , wherein said subject is treated therapeutically with a corticosteroid at a concentration ranging from 5 mg/day to 60 mg/day after administration of the pharmaceutical formulation.
8. The method of claim 1 further comprising the step of determining the absence or the presence of anti-AAV capsid antibodies in the serum of said subject after administration of said pharmaceutical formulation.
9. The method of claim 8 further comprising the step of administering an effective amount of a corticosteroid to said subject after a determination of the presence of anti-AAV capsid antibodies in the serum of said subject is made.
10. A method of increasing Factor VIII protein levels in a subject in need thereof comprising administering a pharmaceutical formulation to said subject by intravenous administration,
wherein the pharmaceutical formulation comprises a recombinant AAV-FVIII virus, sodium phosphate dibasic at a concentration of from about 0.1 mg/ml to about 3 mg/ml, sodium phosphate monobasic monohydrate at a concentration of from about 0.1 mg/ml to about 3 mg/ml, sodium chloride at a concentration of from about 1 mg/ml to about 20 mg/ml, mannitol at a concentration of from about 5 mg/ml to about 40 mg/ml, and poloxamer 188 at a concentration of from about 0.1 mg/ml to about 4 mg/ml,
wherein the recombinant AAV-FVIII virus comprises a vector comprising an AAV2 5′ ITR, a liver specific transcriptional regulatory region, a functionally active FVIII coding region FVIII nucleic acid sequence that encodes a functionally active FVIII protein, a polyadenylation sequence, an AAV2 3′ ITR, and optionally one or more introns inserted into the FVIII coding sequence or between the promoter and the FVIII coding sequence, wherein the functionally active FVIII coding region comprises nucleotides 403-4776 of SEQ ID NO: 1 wherein expression of the FVIII from the recombinant AAV-FVIII in the subject increases the level of FVIII in the subject.
11. The method of claim 10 , wherein said recombinant AAV FVIII virus comprises an AAV5 capsid protein.
12. The method of claim 10 , wherein the pharmaceutical formulation comprises from about 1E12 vg/kg to about 1E14 vg/kg of the recombinant AAV FVIII virus or from about 6E12 vg/kg to about 6E13 vg/kg of the recombinant AAV FVIII virus.
13. The method of claim 10 , wherein the administration of the pharmaceutical formulation results in expression of at least about 5 IU/dl of functional Factor VIII protein in said subject.
14. The method of claim 10 , wherein the treated subject has increased expression of at least about 5 IU/dl of functional Factor VIII protein after administration of the pharmaceutical composition.
15. The method of claim 10 , wherein the treated subject has increased expression of of at least about 1 IU/dl of functional Factor VII protein after administration of the pharmaceutical formulation.
16. The method of claim 10 , wherein said subject is treated with a corticosteroid at a concentration ranging from 5 mg/day to 60 mg/day before or after administration of the pharmaceutical formulation.
17. The method of claim 16 , wherein the corticosteroid treatment is performed prophylactically.
18. The method of claim 16 , wherein the corticosteroid treatment is performed therapeutically.
19. The method of claim 10 , wherein said subject is treated with a corticosteroid at a concentration ranging from 5 mg/day to 60 mg/day over a continuous period of at least 3, 4, 5, 6, 7, 8, 9 or 10 weeks or greater after administration of the pharmaceutical formulation.
20. The method of claim 10 further comprising a step of determining the absence or the presence of anti-AAV capsid antibodies in the serum of said subject after administration of said pharmaceutical formulation.
21. The method of claim 20 further comprising the step of administering an effective amount of a corticosteroid to said subject after a determination of the presence of anti-AAV capsid antibodies in the serum of said subject is made.
22. A method of treating a subject suffering from hemophilia A comprising the steps of (i) determining the absence of anti-AAV capsid antibodies in the serum of said subject, and (ii) administering to said subject a pharmaceutical formulation by intravenous administration,
wherein the pharmaceutical formulation comprises a recombinant AAV-FVIII virus, sodium phosphate dibasic at a concentration of from about 0.1 mg/ml to about 3 mg/ml, sodium phosphate monobasic monohydrate at a concentration of from about 0.1 mg/ml to about 3 mg/ml, sodium chloride at a concentration of from about 1 mg/ml to about 20 mg/ml, mannitol at a concentration of from about 5 mg/ml to about 40 mg/ml, and poloxamer 188 at a concentration of from about 0.1 mg/ml to about 4 mg/ml,
wherein the recombinant AAV-FVIII virus comprises a vector comprising an AAV2 5′ ITR, a liver specific transcriptional regulatory region, a functionally active FVIII coding region FVIII nucleic acid sequence that encodes a functionally active FVIII protein, a polyadenylation sequence, an AAV2 3′ ITR, and optionally one or more introns inserted into the FVIII coding sequence or between the promoter and the FVIII coding sequence, wherein the functionally active FVIII coding region comprises nucleotides 403-4776 of SEQ ID NO: 1 wherein expression of the FVIII from the recombinant AAV-FVIII in the subject treats the hemophilia A.
23. A method of treating a subject suffering from hemophilia A comprising the steps of (i) administering to said subject a pharmaceutical formulation by intravenous administration,
wherein the pharmaceutical formulation comprises a recombinant AAV-FVIII virus, sodium phosphate dibasic at a concentration of from about 0.1 mg/ml to about 3 mg/ml, sodium phosphate monobasic monohydrate at a concentration of from about 0.1 mg/ml to about 3 mg/ml, sodium chloride at a concentration of from about 1 mg/ml to about 20 mg/ml, mannitol at a concentration of from about 5 mg/ml to about 40 mg/ml, and poloxamer 188 at a concentration of from about 0.1 mg/ml to about 4 mg/ml,
wherein the recombinant AAV-FVIII virus comprises a vector comprising an AAV2 5′ ITR, a liver specific transcriptional regulatory region, a functionally active FVIII coding region FVIII nucleic acid sequence that encodes a functionally active FVIII protein, a polyadenylation sequence, an AAV2 3′ ITR, and optionally one or more introns inserted into the FVIII coding sequence or between the promoter and the FVIII coding sequence, wherein the functionally active FVIII coding region comprises nucleotides 403-4776 of SEQ ID NO: 1,
(ii) after administration of said recombinant AAV FVIII virus, determining the absence or the presence of anti-AAV capsid antibodies in the serum of said subject wherein expression of the FVIII from the recombinant AAV-FVIII in the subject treats the hemophilia A.
24. The method of claim 23 which further comprises the step of administering an effective amount of a corticosteroid to said subject after a determination of the presence of anti-AAV capsid antibodies in the serum of said subject is made.
25. The method of any one of claim 1 , 10 , 22 or 23 wherein the pharmaceutical formulation comprises 1.38 mg/ml of the sodium phosphate monobasic monohydrate, 1.42 mg/nil of the sodium phosphate dibasic, 8.18 mg/ml of the sodium chloride, 20 mg/ml of the mannitol and 2.0 mg/ml of the Poloxamer 188 wherein the formulation is stable during storage at <65° C. for at least 2 weeks.